A phase 3, open‐label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
Open Access
- 23 November 2016
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (11), 1860-1867
- https://doi.org/10.1111/jgh.13379
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2013
- Antiviral activity and resistance of HCV NS5A replication complex inhibitorsCurrent Opinion in Virology, 2013
- Novel therapies for hepatitis C — one pill fits all?Nature Reviews Drug Discovery, 2013
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Antimicrobial Agents and Chemotherapy, 2012
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and EgyptLiver International, 2011
- The global health burden of hepatitis C virus infectionLiver International, 2011
- Racial differences in hepatitis C treatment eligibilityHepatology, 2011
- Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysisJournal of Hepatology, 2009
- Natural history of hepatitis C: Its impact on clinical managementHepatology, 2000